English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 62805/95882 (66%)
造访人次 : 3979334      在线人数 : 378
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/41275


    题名: Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia patients
    作者: Lane, Hsien-Yuan;張玉坤;Chang, Yue-Cune;Cheng, Yiao-Cheung;Liu, Guang-Chyi;Lin, Xing-Ru;Chang, Wen-Ho
    贡献者: 淡江大學數學學系
    日期: 2003-03
    上传时间: 2010-01-28 07:09:16 (UTC+8)
    出版者: Physicians Postgraduate Press
    摘要: Background: Predictors for risperidone-related weight gain remain unclear. This study aimed to identify clinical factors influencing body weight in risperidone-treated patients.
    Method: One hundred forty-six newly hospitalized DSM-IV schizophrenia patients with acute exacerbation entered this prospective, 6-week, repeated-measures trial. The mean ± SD risperidone dose was 4.3 ± 1.4 mg/day at week 6. Efficacy, body weight, and tolerability were measured biweekly. Efficacy was assessed with the Positive and Negative Syndrome Scale (PANSS) and the Nurses' Observation Scale for Inpatient Evaluation (NOSIE). For determining the impacts of possible prognostic factors on body weight, we utilized generalized estimating equation methods to control for other variables and the within-subject dependence over repeated assessments.
    Results: After the effects of other factors (including baseline body weight) were adjusted, every 1-week increase in treatment duration raised body weight by 0.442 kg (p < .0001). Increasing baseline body weight by 1 kg reduced weight gain by 0.022 kg (p < .0001). Every 1-year increment in age decreased body weight by 0.052 kg (p < .001). Undifferentiated subtype predicted higher weight by around 0.9 kg than other subtypes (p < .05). Each 1-mg/day increment in risperidone dosage heightened body weight by 0.084 kg (p = .015). Responders (those with PANSS total-score reduction >= 20%) also had higher weight by 0.513 kg on average (p = .007). Specifically, every 1-point diminution in score in PANSS total, PANSS positive, PANSS negative, PANSS cognitive, and NOSIE increased body weight, on average, by 0.029 kg, 0.057 kg, 0.079 kg, 0.079 kg, and 0.035 kg, respectively (p <= .009). Other variables did not have significant influences.
    Conclusion: The results suggest that lower initial body weight, younger age, undifferentiated subtype, higher dosage, and treatment response (for positive, negative, and cognitive symptoms and social functioning) are associated with greater weight gain in acutely ill patients treated with risperidone. Further studies with longer observation and in other populations are needed.
    關聯: Journal of Clinical Psychiatry 64(3), pp.316-320
    DOI: 10.4088/JCP.v64n0314
    显示于类别:[數學學系暨研究所] 期刊論文

    文件中的档案:

    档案 大小格式浏览次数
    index.html0KbHTML70检视/开启

    在機構典藏中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - 回馈